LOXL2 and breast carcinoma: Our lab, and others, have previously analyzed OncomineTM and other breast cancer patient databases demonstrating a correlation between reduced recurrence-free survival (RFS) of breast cancer patients with higher expression of LOXL2 [38, 41, 43] and reduced survival rates with higher expression of OSM/OSMR [70, 71].